RESMED INC

ResMed sells MatrixCare to sharpen its focus on high‑margin sleep‑disorder solutions, but investors must watch the undisclosed sale price and how proceeds boost future growth.

ResMed (RMD) sees a Keybanc price target cut, reflecting macro‑economic headwinds and supply‑chain issues—yet its strong product line and global reach keep investors watching.

ResMed’s stock swings reveal institutional sell‑offs and insider moves, yet analysts see growth via AI, digital insomnia, and cardiometabolic‑sleep markets.

ResMed Inc. is set to release its quarterly earnings on July 31, 2025, with analysts divided on expectations, amidst a broader market context of significant financial disclosures from other major players.

ResMed Inc. is expected to report strong quarterly earnings on July 31, 2025, with analysts projecting an 8.77% increase in revenue and a notable increase in earnings per share.

ResMed Inc. is a strong performer in the health care sector, with a solid track record of growth and innovation, making it a compelling investment opportunity.

ResMed Inc. reports an 8% revenue increase in Q3 2025, driven by strong demand for sleep health products, solidifying its position as a leader in the health care equipment and supplies sector.

ResMed Inc.’s shares surged 5.39% to €199.50 after the company reported an 8% increase in Q3 revenue, driven by strong demand for its sleep health products and strategic initiatives aimed at enhancing shareholder value.